SAT0345 THE IMPACT OF GASTROINTESTINAL INVOLVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC SCLEROSIS
Background: Apart from skin involvement, the gastrointestinal (GI) system is the second most commonly involved organ in systemic sclerosis (SSc), affecting over 80% of the patients. Although rarely being a direct cause of death, it is associated to a high morbidity and to a significant impairment in health-related quality of life (HRQoL). Few data are published considering the influence of GI manifestations in the quality of life of SSc patients. Objectives: The purpose of this study is to characterize the impact of GI involvement in HRQoL in SSc, and to compare it with that in patients with inflammatory bowel disease (IBD). Methods: 29 consecutive SSc patients with GI involvement were selected from a cohort of 44 SSc patients, followed in a single referral centre and classified according to 2013 ACR/EULAR criteria. Comparative analysis was made with 24 consecutive patients with IBD without arthritis (14 Crohn's disease; 10 -ulcerative colitis). Health Assessment Questionnaire (HAQ-DI) and Short Form 36 (SF36), physical component summary (PCS) and mental component summary (MCS) scales, were used to assess HRQoL in both groups. The UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 (UCLA SCTG GIT 2.0) was performed in SSc patients to assess the severity of GI involvement. Clinical data were obtained by medical records review. T-test and Fisher's exact test were used to compare binary variables. Pearson's correlation was used for continuous variables.
Results:
The most common GI segments involved in SSc patients were the esophagus in 90%, the stomach in 60% and the bowel in 48%, while the anorectum was involved in a smaller percentage (10.3%). The mean UCLA SCTG GIT 2.0 score was 0.64±0.51, compatible with a moderate severity, with higher scores obtained for reflux, distention and emotional wellbeing. The mean HAQ-DI score was 1.13±0.57 (0-best health), and the mean PCS and MCS scores were 35.2±9.4 and 35.3±11.4 (100-best health), respectively. These scores were significantly worse than in SSc patients without GI involvement (HAQ-DIp=0.001; PCS -p=0.04 and MCS -p=0.005). There was a significant correlation between higher UCLA SCTG GIT 2.0 scores and worse quality of life evaluated by HAQ-DI (r=0.42, p=0.03), but the same correlation was not found for the SF36 components. Comparing with IBD patients, SSc patients with GI involvement had worse life quality, with statistical significantly higher HAQ-DI (p<0.001) and lower PCS (p<0.001) and MCS (p=0.01) scores. Conclusions: GI involvement in SSc significantly impaired patient's quality of life. The impact of GI involvement in HRQoL of SSc patients was more severe than in IBD patients. Although physical components were relevant, with esophagus being most frequently involved, mental components associated with GI involvement significantly compromised HRQoL in SSc. Therefore, the assessment of SSc patients using clinical severity measure tools, similar to UCLA SCTG GIT 2.0 score, is crucial for a better characterization of the disease and to an optimized clinical approach. Background: Systemic Sclerosis (SSc) is an autoimmune disease, characterized by skin and internal organs fibrosis. Its clinical manifestations are heterogeneous, hence, the definitive diagnosis of SSc rely on scores, such as American College of Rheumatology (ACR) for SSc. Leroy and Medsger, proposed the potential criteria for the classification of early stages of SSc, due to the insufficient sensitivity previous methods. Lately EUSTAR proposed the concept of Very Early SSc, defined by the presence of 3 red flag -RF, Puffy Fingers and ANA; if 2 of these are present, capilaroscopy and specific antibody must be accessed; if one of the last positive, further search for Systemic involvement must be taken in account. Objectives: We propose to: analyse a group of patients that had been diagnosed with early stages of SSc; study the presence of systemic involvement (at the time of diagnosis and throughout the follow-up), and the possible predictors for progression to definitive SSc. Methods: The patients were selected by consulting the clinical data from patients followed in our hospital with diagnose of early stages of SSc. Very Early SSc criteria were used to define early stage SSc. The data concerning red flags, capilaroscopy, specific auto-antibodies, systemic involvement (Gastrointestinal, Pulmonary, Cardiac, Kidney, Muscoloskeletal). Results: We obtained a sample of 70 patients, 65 being female subjects (92,9%), with mean age of diagnosis 47,9 years (SD 13,6). 16 patients (22,9%) were classified as Pre-scleroderma at the admission, 16 as Early SSc (22,9%), 15 (21,4%) as Very Early SSc, 16 (22,9%) as possible SSc, 6 (8, 6%) as Limited SSc (despite not scoring to ACR criteria) and 1 (1,4%) as Sin Scleroderma SSc. 63 patients (90%) had RP, 15 (21,4%) had puffy fingers, 63 (90%) ANA positivity -11 patients (15,7%) had 1 red flag, 45 (64,3%) had 2 red flags and 13 (18,6%) had 3 red flags. 54 patients (78.3%) were positive to specific SSc autoantibodies; 47 patients (71.2%) had capiloroscopy compatible with SSc in different stages (17.1% Early, 12,9% Active, 4,3% Late and 32,9% compatible). 54 patients (77,1%) scored for Very Early SSc. At the moment of the diagnosis, 56 patient (81,2%) had systemic involvement. 34 patients (48,6%) scored to the definitive diagnosis by ACR 2013 criteria, after 2,56 years in mean (SD 2.51) of first diagnosis. No correlation was found in what concerns to predictors of progression to SSc or systemic involvement. Conclusions: This study shed a light on the importance of the recognition of SSc's early stages, since a significant part of these patients have systemic involvement at the moment of diagnosis, yet not scoring to ACR 2013 criteria. Almost half of the patients scored to definite diagnosis of SSc at the moment of the last appointment. The importance of these findings rely on the possibility to identify systemic involvement and address it in time to prevent/delay further disease progression.
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